<DOC>
	<DOCNO>NCT01178996</DOCNO>
	<brief_summary>The purpose study determine safety efficacy 48 week treatment Thymosin alpha 1 ( Talpha1 ) combination pegylated interferon ( PEGIFN ) alpha2a ribavirin ( RBV ) adult patient chronic hepatitis C ( CHC ) already treat , respond previous course PEGIFN alpha plus RBV combination therapy , comparison concurrent group treat PEG IFN alpha2a combination RBV placebo .</brief_summary>
	<brief_title>Thymosin Alpha-1 Combination With Peg-Interferon Alfa- 2a Ribavirin Therapy Chronic Hepatitis C Nonresponsive Combination IFN Ribavirin .</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Thymalfasin</mesh_term>
	<criteria>1 . Signed write informed consent 2 . Age 18 3 . Presence HCV RNA measure quantitative PCR 4 . Non responder previous approved dos therapy PEGinterferon alpha plus ribavirin . Patients must treat least 12 week document HCV RNA quantitative showing major 2 log10 HCV RNA reduction patient treat least 24 week document HCV RNA qualitative show virological response ( viral RNA clearance ) 5 . Liver biopsy consistent diagnosis chronic hepatitis C histological cirrhosis . Biopsy require patient produce biopsy perform within year precede randomization day perform least 6 month end latter course therapy 6 . Washout period least 6 month previous therapy PEGinterferon alpha plus ribavirin 7 . Negative pregnancy test prior ( 24 hour ) first study medication dose 1 . Use systemic corticosteroid within 6 month entry 2 . More one previous course therapy PEGinterferon alpha plus ribavirin 3 . Any liver disease 4 . Decompensated liver disease base history hepatic encephalopathy , bleed oesophageal varix , ascites 5 . Decompensate advance liver cirrhosis ( ChildPugh B C ) 6 . HIV infection diagnose HIV seropositivity confirm Western blot 7 . Insulindependent Diabetes Mellitus 8 . Severe haemoglobinopathy 9 . Positive liver kidney microsomal auto antibody 10 . Positive anti thyroid antibodies 11 . Pregnancy document urine pregnancy test 12 . Alcohol intravenous drug abuse within previous 1 year 13 . Patients poor medical psychiatric condition , nonmalignant systemic disease , opinion Investigator , would make unlikely patient could complete study protocol 14 . Any indication patient would comply condition study protocol 15 . Previous treatment thymosin alpha 1 16 . Patients know hypersensitivity PEGinterferon ribavirin 17 . Patients history severe depression require either hospitalization electroshock therapy depression associate suicide attempt 18 . Simultaneous participation another investigational drug study participation clinical trial involve investigational drug within 3 month study entry 19 . Presence serious pulmonary cardiovascular disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2010</verification_date>
</DOC>